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for Early Diagnosis
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Abstract
The recent and revolutionary paradigm shift involving novel therapeutics for the
treatment of rheumatoid arthritis (RA) has called for changes in the early diagnosis of
RA. Physicians now need to diagnose RA earlier, and with greater accuracy, in order
to initiate effective definitive treatment as early as possible. However, due to the
complexity and diverseness of RA, we still do not have comprehensive diagnostic
criteria for RA readily available. To find a solution to this challenge, we aimed to
develop practically useful criteria which integrate gadolinium (Gd) contrast-
enhanced magnetic resonance imaging (MRI) findings with clinical manifestations of
the disease. These diagnostic criteria we propose, the “diagnostic criteria for early RA
with MRI findings,” are composed of two domains. The first domain consists of
clinical findings suggestive of RA, which include both entry criteria—i.e.,
polyarthralgia of hands (joint pain of three or more joint areas confirmed by a
physician), and exclusion criteria—i.e., exclusion of other rheumatic conditions
including systemic lupus erythematosus (SLE), dermatomyositis and polymyositis
(PM/DM), mixed connective tissue disease (MCTD), primary Sjögren’s syndrome
(SS), and Behçet’s disease (BD). The second domain constitutes MRI criteria, which
represent Gd-enhanced MRI findings indicating bilateral synovial enhancement seen
in any joints of the proximal interphalangeal (PIP), metacarpophalangeal (MCP), or
wrist joints. RA is defined by fulfilling all conditions of both domains. Our prospec-
tive study demonstrated that these criteria for the diagnosis of early RA, incorporat-
ing MRI findings with physical manifestations, can successfully distinguish patients
with RA from those with other mimicking conditions, showing a sensitivity of 96%,
specificity of 86%, and accuracy of 92%. When a case does not meet the criteria, RA
can be ruled out with a high negative predictive value of 95%. We believe our
“diagnostic criteria for early RA with MRI findings” can greatly help to solve unmet
diagnostic needs in the early treatment of RA.
Keywords: rheumatoid arthritis (RA), early RA, magnetic resonance imaging
(MRI), gadolinium (Gd) contrast-enhanced MRI, diagnostic criteria
1. Introduction
Rheumatoid arthritis (RA), an autoimmune systemic inflammatory disease
marked by progressive joint destruction, disability, and mortality, is the most
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common connective tissue disease (CTD), occurring in 1–2% of the population, and
more frequently in women. The disease is primarily characterized by synovial
inflammation which leads to an erosive/destructive polyarthropathy, predomi-
nantly affecting the peripheral joints, but also with extra-articular manifestations
including subcutaneous nodules, skin ulceration, scleritis/episcleritis, pericarditis,
splenomegaly, and a variety of pleuro-pulmonary disorders which may develop
during its clinical course.
1.1 Etiology
Although the etiology of RA has not yet been fully elucidated, it is recognized as
a multifactorial disease associated with genetic susceptibility, environmental trig-
gering, hormonal predisposition, and possibly infections. Genetic risk factors
include human leukocyte antigen (HLA)-DR4, in particular, HLA–DRB1 alleles
encoding a common amino acid sequence (the “shared epitope”) in the third
hypervariable region of the DRB1 molecule [1]. The HLA-DRB1*04 alleles (HLA-
DRB1*0401, *0404, *0408, and *0405) show the strongest association with RA,
especially with anti-citrullinated protein antibody (ACPA)-positive RA [2]. These
alleles have in common a highly conserved sequence between amino acids 67 and 74
along the α-helix derived from the DRβ chain, which forms one side of the antigen-
binding site of the DR molecule [3]. Studies have shown that the shared epitope
alleles may preferably present citrullinated peptides [4]. In addition to the HLA
locus, recent genome-wide association studies (GWAS) have revealed many high-
risk RA susceptibility genes, such as CD244, PADI4, SLC22A2, PTPN22, CTLA4,
and STAT4 [5]. However, except for some loci, the function of most of these RA
risk loci remains unclear.
Among multiple environmental and behavioral risk factors that have been stud-
ied, cigarette smoking is identified as the strongest trigger for RA, especially in
populations with a genetic predisposition [6]. Smoking may induce citrullination of
peptide antigens present in the lungs, and the shared epitope alleles interact with
smoking in the triggering of anti-citrulline immunity that may lead to ACPA-
positive RA [7–9]. Two risk factors for RA, HLA-DRB1 shared epitope alleles and
smoking, are also linked to adult periodontitis [10, 11]. Periodontitis is mainly
induced by Porphyromonas gingivalis (P. gingivalis) infection, which, by subverting
host immune defenses, leads to overgrowth of oral commensal bacteria causing
inflammatory tissue destruction [12, 13]. This condition is characterized by the
accumulation of large amounts of citrullinated proteins with similar patterns of
hypercitrullination found in RA synovial fluid [14].
Since the 1980s, a number of studies have shown a possible association between
RA and periodontitis, suggesting pathological similarities [15]. However, significant
advances were not made until 1999, when it was found that P. gingivalis secretes a
peptidylarginine deiminase (PAD)-like enzyme [16]. This was followed by a
hypothesis by Rosenstein that periodontitis drives RA through the production of
citrullinated antigens by P. gingivalis [17]. A periodontal pathogen, P. gingivalis,
expresses an enzyme with PAD activity that mediates citrullination, in which argi-
nine residues are deiminated to citrulline residues. This process may produce anti-
bodies involved in the etiology of RA by breakdown of immunological tolerance to
citrullinated antigens. To date, four citrullinated autoantigens have been defined:
citrullinated fibrinogen, vimentin, collagen type II, and α-enolase [10, 11].
Although ACPAs, the autoantibodies directed against citrullinated peptides and
proteins, are highly specific for RA, it should be noted that the enzyme-linked
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immunosorbent assay is based on synthetic cyclic citrullinated peptides (CCPs) and
not equivalent to the detection of antibodies to citrullinated proteins in vivo.
Currently, both smoking and P. gingivalis are plausible causative factors that
warrant further investigation into the gene/environment/autoimmunity triad of RA
etiology [18, 19].
1.2 Immunopathology of synovitis
The hallmark feature of arthritis in RA pathology is “synovitis,” the
inflammation of synovial membranes lining the inner surface of joint cavities,
tendinous sheaths, and bursae. An autoimmune-mediated inflammatory response
in joints leads to the formation of abnormal synovial tissue growth, the “rheumatoid
pannus,” which invades the joint space as well as adjacent components including
bones and their protective layer of articular cartilage. The pathological milieu of the
inflammatory synovial compartment, characterized by leukocyte infiltration
comprising innate immune cells, e.g., monocytes, dendritic cells, mast cells, and
innate lymphoid cells, as well as adaptive immune cells, e.g., Th1 and Th17 cells, B
cells, plasmablasts, and plasma cells, is governed by a complex network of cytokines
and chemokines. Dynamisation of this network leads to aggravation of the inflam-
matory response by activating endothelial cells and fibroblasts and ultimately trig-
gering osteoclast generation through receptor activation of nuclear factor κ B ligand
(RANKL) on T cells, B cells, and fibroblasts, with its receptor RANK on macro-
phages, dendritic cells, and preosteoblasts [20]. In the context of such inflammatory
pathway, the key cytokines, i.e., tumor necrosis factor-α (TNF-α) and interleukin 6
(IL 6), play a critical role, as evidenced by therapeutic interventions targeting these
factors resulting in remarkable clinical improvement in arthritis [21].
The recent work has shed light on a new scenario, in which the IL23/Th17 axis
plays an essential role in bone loss, by favoring the generation of pathogenic
ACPAs, via the secretion of IL-21 and IL-22, and by facilitating osteoclastogenesis,
via the secretion of IL-17 [22]. As our understanding of molecular occurrence before
the onset of RA has increased, it became evident that the interplay between mucosal
events is relevant in the pathogenesis of the disease, in which oral and lung mucosa,
under the stimuli of environmental factors, represents sites of ACPA production,
while the intestinal dysbiosis increases the inflammatory state through increased
Th17 polarization and IL-23/IL-17 axis activation (Figure 1) [23]. The recent
discovery of the effect of ACPAs on osteoclastogenesis and on periarticular IL-8
production also suggests a mechanism that accounts for the transition from
systemic autoimmunity to clinical manifestations [24].
1.3 Treatment of RA
Three decades ago, the treatment for RA was guided by a step-up approach, i.e.,
“the pyramid approach,” in which nonsteroidal anti-inflammatory drugs (NSAIDs)
and other conservative measures constituted first-line treatment, subsequently
moving to more potent and cytotoxic drugs for persistent symptoms or progressive
structural damage [25] (see Figure 2). This approach is no longer valid as RA has
been recognized as causing substantial morbidity and mortality among those on the
pyramid approach. Since then, RA treatment strategy has advanced dramatically.
The routine administration of conventional disease-modifying antirheumatic drugs
(cDMARDs), such as the anchor drug methotrexate, enabled physicians to ease RA
symptoms with substantially better control of cartilage and bone erosion [26, 27]
(Table 1).
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Figure 1.
Mucosa-environment interactions in the immuno-pathogenesis of RA. In the oral and lung mucosa, the stimuli
of periodontal pathogens or environmental factors elicit production of citrullinated proteins, directly or through
NETosis*, and consequently result in ACPA production in subjects at risk. (1) At the periodontal level,
Porphyromonas gingivalis (P. gingivalis) generates citrullinated peptides through PPAD. Moreover, through
gingipains (Gp) (a family of proteases secreted by P. gingivalis), P. gingivalis increases Th17 polarization and
induces NETosis. Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans) can also elicit the
formation of citrullinated peptides, through the production of leukotoxin A (Lxt-A) and the induction of
NETosis. Citrullinated peptides (Cit-P), recognized by specific B cells, induce ACPA production. (2) In the
lung mucosa, smoke and air pollutants generate the formation of citrullinated antigens and NETosis. Mucosa
reacts through the formation of iBALT (inducible bronchus associated lymphatic tissue) and elicits the local
production of ACPAs, which can be detected in local secretions. (3) In systemic circulation, there is an increase
of circulating Th17 and a reduction of Treg. T cells present an abnormal hypoglycolytic and hyperproliferative
phenotype, and show an increased production of pro-inflammatory cytokines, such as IL-17. (4) In gut mucosa,
dysbiosis of the intestinal microbiota inhibits the normal induction of Treg. Pathobiont species stimulate the
activation of dendritic cells (DC), macrophages and innate lymphoid cells 3 (ILC3), leading to the
polarization towards Th17, and the activation of the IL-23/IL-17 axis. Locally-produced Th17 can migrate
through systemic circulation to other sites, inducing inflammation, abnormal Ig glycosylation, and iBALT
formation. Specific B cells directed against luminal antigens can be activated in Peyer’s patches or in local lymph
nodes, migrating back in lamina propria where they produce secretory immunoglobulins (sIgs). Some of these B
cells recognize antigens that cross-react with self-antigens via molecular mimicry. Finally, inflammatory cells
and ACPAs lead to the onset of arthritis. Cit-p: citrullinated proteins; PPAD pathogen PAD; Gp: gingipains;
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In addition, as the role of several key proinflammatory cytokines including
TNF-α and IL-6, and cell-associated targets such as CD20 and co-stimulation
molecules CD80/86, has been clarified, the treatment paradigm has changed with
the advent of targeted biological therapies [28]. The emergence of a number of
potent biological DMARDs (bDMARDs) has brought about a new therapeutic era
that emphasizes the importance of early and aggressive treatment to prevent joint
damage and induce remission [26, 29–32] (Table 1). It has become thoroughly
evident that early suppression of disease activity is crucial. For instance, a large RA
trial cohort study validated that early changes in MRI measures independently
predicted X-ray and MRI progression, robustly suggesting the necessity of early
intervention [33].
This conceptual trend in the treatment of RA was followed by new approval of
the targeted synthetic DMARDs (tsDMARDs), such as small-molecule inhibitors of
Janus kinase (JAK) enzymes [32, 34] (Table 2). The JAK family includes four
members, JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). The different JAK
isoforms, and the downstream signal transducer of activators of transcription
Ltx-A: leukotoxin A; iBALT: inducible bronchus associated lymphatic tissue; sIgs: secretory immunoglobulins;
ILC3: innate lymphoid cells 3; DC: dendritic cells; IL: interleukin.
*NETosis—the role in RA etiology: neutrophil extracellular traps (NETs) are chromatin-derived extracellular
“spider’s webs” that are expelled from neutrophils in response to infection or inflammatory stimuli. They were
first described as an alternative defense mechanism by which neutrophils trap and kill microbes. NET-release
represents a novel, unique form of cell death that is characterized by the discharge of decondensed chromatin
and granular contents to the extracellular space, and is referred to as “NETosis”, distinct from apoptosis and
necrosis. Afterwards, it has become clear that NETs also render autoantigens in autoimmune diseases. NETs
have been implicated in the development of autoimmunity in certain conditions such as RA and SLE through an
exposure of externalized intracellular neoepitopes e.g., citrullinated peptides in RA and dsDNA and nuclear
proteins in SLE. Currently, emerging evidence implicates NETs as a source of citrullinated neoepitopes in RA,
causing loss of immune tolerance and development of autoantibodies to citrullinated proteins (ACPA).
Citrulline residues in aggrecan and vimentin are preferentially recognized by antigen-presenting cells in
individuals who carry the HLA-DRB1*04:01/04 allele, providing a molecular explanation for the strong
association between this allele and the development of RA. Modified from Lucchino et al. [23].
Figure 2.
The traditional treatment pyramid for RA, long since abandoned. Modified from Schumacher [62].
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(STAT) proteins, are expressed in synovial tissue and cells [35]. The JAK–STAT
pathway is currently thought to be an evolutionarily conserved signaling pathway
engaged by diverse cytokines, interferons, growth factors, and hormones,
providing a simple and elegant machinery whereby extracellular molecules regulate
gene expression [36]. Each JAK family member selectively binds different receptor
chains (Figure 3).
Many proinflammatory cytokines involved in RA pathogenesis bind to a specific
group of type I and type II cytokine-receptors, which are structurally distinct from
DMARD Mechanism for rheumatoid arthritis Adverse effects Monthly
cost†
Nonbiologic*
More commonly used
Methotrexate Inhibits dihydrofolate reductase Liver effects, teratogenesis, hair
loss, oral ulcers
$
Leflunomide (Arava) Inhibits pyrimidine synthesis Liver effects, gastrointestinal
effects, teratogenesis
$
Hydroxychloroquine
(Plaquenil)
Antimalarial, blocks toll-like receptors Rare ocular toxicity $$
Sulfasalazine
(Azulfidine)
Folate depletion, other mechanisms
unknown
Anemia in G6PD deficiency,
gastrointestinal effects
$
Minocycline (Minocin) Antimicrobial, other mechanisms
unknown
Drug-induced lupus
erythematosus, Clostridium
difficile colitis
$
Less commonly used
Gold sodium thiomalate Inhibits antigen processing, decreases
cytokines (TNF, interleukin-6)
Skin, heme, renal effects $$
Penicillamine
(Cuprimine)
Chelates metal, other mechanisms
unknown
Heme, renal effects $$
Cyclophosphamide Nitrogen mustard alkylating agent, cross-
links DNA
Infertility, cancer, hemorrhagic
cystitis
$$
Cyclosporine
(Sandimmune)
Calcineurin inhibitor, decreases
interleukin-2
Hypertension, renal effects,
hirsutism
$$
Biologic*
Anti-TNF agents
Adalimumab (Humira) Anti-TNF-α TB, opportunistic infection $$$
Certolizumab pegol
(Cimzia)
Anti-TNF-α, pegylated TB, opportunistic infection $$$
Etanercept (Enbrel) Anti-TNF-α, receptor TB, opportunistic infection $$$
Golimumab (Simponi) Anti-TNF-α TB, opportunistic infection $$$
Infliximab (Remicade) Anti-TNF-α TB, opportunistic infection,
infusion reaction
$$$
Other biologic agents
Abatacept (Orencia) Costimulator blocker, cytotoxic T
lymphocyte antigen 4
Opportunistic infection $$$
Anakinra (Kineret) Anti-interleukin-1 receptor blocker Opportunistic infection,
injection site pain
$$$
Rituximab (Rituxan) Anti-CD20, eliminates B cells Infusion reaction, opportunistic
infection, progressive multifocal
leukoencephalopathy
$$$$
Tocilizumab (Actemra) Anti-interleukin-6 receptor blocker Opportunistic infection $$$
G6PD = glucose-6-phosphate dehydrogenase; TB = tuberculosis; TNF = tumor necrosis factor.
Adapted from Wasserman [26].
*Nonbiologic drugs listed in approximate order of priority, biologic drugs listed in alphabetical order.
†$ = $30 to $100; $$ = $100 to $1000; $$$ = $1000 to $5000; $$$$ = more than $5000.
Table 1.
Biologic and nonbiologic DMARDs.
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other receptors such as those that bind TNF and IL-1. Since cytokines binding type I
and II receptors are dependent on the JAK–STAT pathway for signal transduction,
several JAK inhibitors (“jakinibs”) with variable degrees of selectivity and specific-
ity for the JAK enzymes have been tested in RA. Tofacitinib and baricitinib are the
first orally available JAK inhibitors with selectivity for JAK 1 and 3 and JAK 1 and 2,
respectively. Both have demonstrated rapid improvements in multiple outcome
measures [37].
The latest 2019 update of the European League Against Rheumatism (EULAR)
recommendations for the management of RA with synthetic and biological disease-
modifying antirheumatic drugs provided consensus including the statement which
elevated the JAK inhibitors (“tsDMARDs”), to the same recommendation level as
bDMARDs [38]. The 2019 version of general overview of the RA management
recommendations in form of an algorithm is depicted in Figure 4 [32].
Synthetic DMARDs
Conventional synthetic DMARDs
• Unknown target: methotrexate, sulfasalazine, chloroquine, hydroxychloroquine and gold salts
• Known target: that is, dihydroorotate-dehydrogenase for leflunomide
Targeted synthetic DMARDs
• Janus kinase 1 (JAK1) and JAK2: baricitinib
• JAK1, JAK2 and JAK3: tofacitinib
Biological DMARDs
Biological originator DMARDs
• Tumour necrosis factor: adalimumab, certolizumab, etanercept, golimumab and infliximab
• IL-6 receptor: tocilizumab and sarilumab
• IL-6: clazakizumab, olokizumab and sirukumab
• CD80 and CD86 (involved in T cell co-stimulation): abatacept
• CD20 (expressed by B cells): rituximab
Adapted from Smolen et al. [34].
Table 2.
Synthetic DMARDs and biologic DMARDs.
Figure 3.
The JAK–STAT pathway. The four JAKs (JAK1, JAK2, JAK3,TYK2) are selectively bound to and therefore
mediate signaling for various cytokine and hormone receptors. Different cytokines also have a propensity to
activate certain STATs. Mutations in many of the gene encoding JAKs and STATs (indicated by an asterisk )
have been linked to human disease. A large number of medications targeting JAKs and, to a lesser degree, STATs
(indicated by a ) are being developed and used to treat human disease. Adapted from O’Shea et al. [36].
7
Growing Need for Diagnostic Precision in Rheumatoid Arthritis: Proposal of MR Imaging…
DOI: http://dx.doi.org/10.5772/intechopen.92989
Figure 4.
Presentation of the 2019 update of the EULAR RA management recommendations in form of an algorithm.
This is an abbreviated version aiming to provide a general overview, but it must be borne in mind that the
algorithm cannot be separated from the details presented in the discussion of the individual recommendations in
the paper which are part and parcel of these recommendations. ACPA, anti-citrullinated protein antibody;
ACR, American College of Rheumatology; bDMARDs, biological DMARDs; bsDMARD, biosimilar DMARDs;
csDMARDs, conventional synthetic DMARDs; DMARDs, disease-modifying antirheumatic drugs; EMA,
European medicines agency; EULAR, European league against rheumatism; FDA, Food and Drug
Administration; IL-6R, interleukin 6 receptor; JAK, Janus kinase; MTX, methotrexate; RA, rheumatoid
arthritis; RF, rheumatoid factor; TNF, tumor necrosis factor; tsDMARDs, targeted synthetic DMARDs.
Adapted from Smolen et al. [32].
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1.4 Unmet diagnostic needs in RA
Given such revolutionary paradigm shift in the therapeutics for RA, it is
warranted that we now readjust our focus towards innovative changes in the early
diagnosis of RA. Today, physicians are required to diagnose RA earlier and with
greater accuracy in order to start effective treatment as soon as possible and with
greater confidence. Nonetheless, the reality in clinical practice is not simple at all.
The diagnosis of RA continues to be mostly based on a combination of symptoms,
signs, and results of investigations. However, because of the great variety of indi-
vidual clinical presentations in RA, and since no single symptom or sign is specific
for RA, accurate diagnosis may be hindered, especially in the early stages of disease
when hallmark joint destruction may be absent or missed. Obviously, classification
criteria for RA do exist, with a series of criteria having been created to define classic
disease for clinical and both epidemiological studies. However, the application of
classification criteria can give rise to both false-positive and false-negative classifi-
cations compared to the true clinical diagnosis [39]. In this context, we still do not
have comprehensive diagnostic criteria of RA in the real clinical world.
Currently, among the clinically available imaging modalities, magnetic reso-
nance imaging (MRI) is thought to be the most sensitive, and available evidence has
led to its increasing use for assessing the active synovitis and bone damage central to
many clinical RA studies including several of our previous reports [40–43].
Thus, to find a solution to the challenge of early diagnosis of RA, we aimed to
develop practically useful diagnostic criteria which integrate gadolinium (Gd)
contrast-enhanced magnetic resonance imaging (MRI) findings into clinical
manifestations of the disease, which we will attempt to describe herein.
2. Attempts for accurate or earlier diagnosis of RA
2.1 The 1987 ACR classification criteria for RA: “old but gold”standard
As mentioned above, currently no validated diagnostic criteria exist for RA. By
contrast, a few sets of classification criteria have been developed and modified over
time. Classification criteria are standardized definitions that are primarily aimed to
collect homogenous cohorts of patients with typical disease, primarily for clinical
and epidemiological studies [44]. Although they are not intended to capture the
entire universe of patients with the disease, they may provide some framework to
support diagnosis and are often used in this way in daily practice.
The most historically notable classification criteria which have been used in RA
are the American College of Rheumatology (ACR) criteria revised in 1987 by the
American Rheumatism Association, published by Arnett et al. [45] (Table 3). At
the time the 1987 criteria were presented, sensitivity and specificity were reported
to be 91–94% and 89%, respectively. They have been widely applied for diagnosis,
as well. However, the 1987 criteria, which were developed based on established
patients with an average disease duration of 7.7 years, have come to be recognized
as having poor performance for diagnosing early RA. A systemic literature review
by Banal et al. of 138 publications comprising 7438 patients (including 3883 cases of
RA) reported that the sensitivity and specificity of the 1987 criteria (in the list
format) for early RA (<1 year) were 77% (68–84%) and 77% (68–84%), respec-
tively, compared to 79% (71–85%) and 90% (84–94%), respectively, for established
RA (>1 year) [46]. The Norfolk Arthritis Register report by Harrison et al. demon-
strated that only 50% of RA patients fulfilled the 1987 criteria at 6 months and only
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80% even at 2 years after enrolment [47]. Thus, the 1987 criteria do not appear to be
well-suited as a diagnostic measure of short-duration RA. Emerging evidence on the
response of arthritis to early intervention with DMARDs indicates the existence of
“a window of opportunity in RA,” a time during which aggressive treatment
accounts for long-term benefits in outcome. Therefore, to meet clinical needs,
better diagnostic measures are required to identify RA patients at the earliest stages
of the disease.
2.2 The 2010 ACR/EULAR classification criteria for RA
Since 2007, the ACR and EULAR have been working collaboratively to create new
classification criteria for RA, which were finally published in 2010 [48] (Table 4).
The 2010 criteria are an effort to facilitate earlier diagnosis of RA in patients who may
not meet the 1987 ACR criteria. For example, they do not include the presence of
rheumatoid nodules or radiographic erosive changes, both of which are less likely in
early RA. The 2010 criteria consist of a classification scoring system, laying emphasis
on small joint involvement as well rheumatoid factor (RF) or ACPA seropositivity. It
should be noted that RF is not specific for RA and can be detected in patients with
other disorders, such as viral hepatitis C, and in healthy elderly individuals [49, 50]
(Table 5). Although ACPA is more specific for RA, it may be present in other
rheumatic diseases and some infectious diseases [51] (Table 6). We know approxi-
mately 50–80% of patients with RA have RF, ACPA, or both [52]. Acute-phase
reactants such as C-reactive protein and erythrocyte sedimentation rate are also part
of the criteria. As shown inTable 4, in the new classification criteria, the definition of
RA requires at least a single clinically swollen joint for inclusion entry and the absence
Criterion Description
Morning stiffness Morning stiffness in and around the joints that lasts at least 1 hour before
maximal improvement
Arthritis in three or
more areas
At least three joint areas that simultaneously have soft-tissue swelling or fluid
(not bone overgrowth alone) observed by a physician (the 14 possible joint
areas are the right and left PIP, MCP, wrist, elbow, knee, ankle, and MTP
joints)
Arthritis of hand
joints
At least one of the following joint areas is swollen: wrist, MCP, or PIP joint (see
description of second criterion)
Symmetric arthritis Simultaneous involvement of the same joint areas listed for the second
criterion on both sides of the body (bilateral involvement of PIP, MCP, or MTP
joints is acceptable without absolute symmetry)
Rheumatoid nodules Subcutaneous nodules over bone prominences or extensor surfaces or in
juxtaarticular regions observed by a physician
Serum rheumatoid
factor
Demonstration of abnormal amounts of serum rheumatoid factor with any
method that has yielded positive results in <5% of healthy control subjects
Radiographic changes Changes typical of rheumatoid arthritis on posteroanterior radiographs of the
hand and wrist; these must include erosions or unequivocal bone
decalcification localized to or most marked adjacent to the involved joints
(osteoarthritic changes alone do not qualify)
Note: For classification purposes, a patient is said to have rheumatoid arthritis if he or she has satisfied at least four of
the seven criteria. The first four criteria must be present for at least 6 weeks. Patients with two clinical diagnoses are
not excluded. MCP = metacarpophalangeal, MTP = metatarsophalangeal, PIP = proximal interphalangeal.
Adapted from Arnett et al. [45].
Table 3.
The ACR 1987 revised criteria for the classification of rheumatoid arthritis.
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of other diseases (alternative diagnoses) better explaining the clinical symptoms.
Thereafter, the classification is based on a total score from individual items in four
domains including the number of involved joints, serological abnormalities, elevated
acute-phase reactants, and duration of symptoms.
Score
Target population (Who should be tested?): Patients who
1. have at least 1 joint with definite clinical synovitis (swelling)*
2. with the synovitis not better explained by another disease†
Classification criteria for RA (score-based algorithm: add score of categories A–D; a score of
≥6/10 is needed for classification of a patient as having definite RA)‡
A. Joint involvement§
1 large joint¶ 0
2–10 large joints 1
1–3 small joints (with or without involvement of large joints)# 2
4–10 small joints (with or without involvement of large joints) 3
>10 joints (at least 1 small joint)** 5
B. Serology (at least 1 test result is needed for classification)††
Negative RF and negative ACPA 0
Low-positive RF or low-positive ACPA 2
High-positive RF or high-positive ACPA 3
C. Acute-phase reactants (at least 1 test result is needed for classification)‡‡
Normal CRP and normal ESR 0
Abnormal CRP or abnormal ESR 1
D. Duration of symptoms§§
<6 weeks 0
≥6 weeks 1
*The criteria are aimed at classification of newly presenting patients. In addition, patients with erosive disease typical of
rheumatoid arthritis (RA) with a history compatible with prior fulfillment of the 2010 criteria should be classified as
having RA. Patients with longstanding disease, including those whose disease is inactive (with or without treatment) who,
based on retrospectively available data, have previously fulfilled the 2010 criteria should be classified as having RA.
†Differential diagnoses vary among patients with different presentations, but may include conditions such as systemic
lupus erythematosus, psoriatic arthritis, and gout. If it is unclear about the relevant differential diagnoses to consider, an
expert rheumatologist should be consulted.
‡Although patients with a score of <6/10 are not classifiable as having RA, their status can be reassessed and the criteria
might be fulfilled cumulatively over time.
§Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by imaging evidence
of synovitis. Distal interphalangeal joints, first carpometacarpal joints, and first metatarsophalangeal joints are
excluded from assessment. Categories of joint distribution are classified according to the location and number of
involved joints, with placement into the highest category possible based on the pattern of joint involvement.
¶“Large joints” refers to shoulders, elbows, hips, knees, and ankles.
#“Small joints” refers to the metacarpophalangeal joints, proximal interphalangeal joints, second through fifth
metatarsophalangeal joints, thumb interphalangeal joints, and wrists.
**In this category, at least 1 of the involved joints must be a small joint; the other joints can include any combination of
large and additional small joints, as well as other joints not specifically listed elsewhere (e.g., temporomandibular,
acromioclavicular, sternoclavicular, etc.).
††Negative refers to IU values that are less than or equal to the upper limit of normal (ULN) for the laboratory and
assay; low-positive refers to IU values that are higher than the ULN but ≤3 times the ULN for the laboratory and assay;
high-positive refers to IU values that are >3 times the ULN for the laboratory and assay. Where rheumatoid factor (RF)
information is only available as positive or negative, a positive result should be scored as low-positive for RF. ACPA =
anti–citrullinated protein antibody.
‡‡Normal/abnormal is determined by local laboratory standards. CRP = C-reactive protein; ESR = erythrocyte
sedimentation rate.
§§Duration of symptoms refers to patient self-report of the duration of signs or symptoms of synovitis (e.g., pain,
swelling, tenderness) of joints that are clinically involved at the time of assessment, regardless of treatment status.
Adapted from Aletaha et al. [48].
Table 4.
The 2010 ACR/EULAR classification criteria for rheumatoid arthritis.
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The primary aim of creating the 2010 criteria was described as not for develop-
ing diagnostic criteria but rather to facilitate the study of patients with earlier stages
of RA. However, they have become widely used as an aid in the diagnosis of RA in
Disease RF frequency, %
Arthritis
Rheumatoid arthritis
Juvenile idiopathic arthritis
Psoriatic arthritis
Reactive arthritis
70–90
5
<15
<5
Other connective tissue diseases
Primary Sjögren’s syndrome
Mixed connective tissue disease
Systemic lupus erythematosus
Systemic sclerosis
Dermatomyositis/polymyositis
Systemic vasculitides
75–95
50–60
15–35
20–30
20
5–20
Infectious diseases
Bacterial infections
Subacute bacterial endocarditis
Chlamydia pneumoniae infection
Klebsiella pneumoniae infection
Syphilis primary-tertiary
Tuberculosis
Viral infections
Coxsackie B virus infection
Dengue virus infection
EBV and CMV infections
Hepatitis A, B and C virus infection
HCV infection
Herpes virus infection
HIV infection
Measles
Parvovirus infection
Rubella
Parasitic
Chagas
Malaria
Onchocerciasis
Toxoplasmosis
40
8–37
15
15
10
20
25
40–76
10–15
10–20
8–15
10
15
15–25
15–18
10
10–12
Other diseases
Mixed cryoglobulinemia type II
Liver cirrhosis
Primary biliary cirrhosis
Malignancy
After multiple immunizations
Chronic sarcoidosis
100*
25
45–70
5–25
10–15
5–30
Healthy individuals
Healthy 50-year olds
Healthy 70-year olds
5
10–25
*Monoclonal IgM rheumatoid factors.
RF: rheumatoid factor; CMV: cytomegalovirus; EBV: Epstein-Barr virus; HCV: hepatitis C virus; HIV: human
immunodeficiency virus.
Adapted from Ingegnoli et al. [50].
Table 5.
Rheumatoid factor frequency in different diseases and conditions.
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clinical practice, resulting in helping clinicians and researchers to become aware of
the 2010 criteria’s strengths and limitations as well. First of all, regarding entry
criterion of the target population, the sentence “patients who with the synovitis not
better explained by another disease” is quite tricky. Annotation states that “Differ-
ential diagnoses differ in patients with different presentations, but may include
conditions such as systemic lupus erythematosus, psoriatic arthritis, and gout. If it is
unclear about the relevant differential diagnosis to consider, an expert rheumatolo-
gist should be consulted.”Most rheumatologists know that there are many mimick-
ing conditions to be distinguished from RA. The easy “ask-the-expert” attitude may
be paradoxical to the principle of having criteria. Furthermore, Kaneko et al. iden-
tified a problem with the scoring criteria, which weigh relatively heavily in favor of
serology, reporting a sensitivity as low as 15.8% when both RF and ACPA are
negative. For instance, a seronegative person having 10 swollen joints for >6 weeks,
with elevated CRP and ESR and destructive joint disease, would not achieve a total
score of 6 per the new criteria [53]. Thus, several limitations of the 2010 criteria
have already been recognized which hinder their use in daily practice.
3. Notion of early RA
Since early diagnosis and treatment with newly developed antirheumatic drugs
including bDMARDs and tsDMARDs have been advocated for patients with RA, the
understanding of “early” RA has changed. Formerly, early RA denoted disease of
less than 2 years, or used to be sometimes less than 12 months duration. However,
today, many rheumatologists may even see patients with symptom duration of less
than 6 weeks. While the definition of early RA is still heterogeneous, two-thirds of
N ACPA* positive, no. (%)
Psoriatic arthritis 1343 115 (8.6)
Systemic lupus erythematosus 1078 84 (7.8)
Sjögren’s syndrome 609 35 (5.7)
Spondylarthropathy 431 10 (2.3)
Scleroderma/CREST syndrome 380 26 (6.8)
Hepatitis C/cryoglobulinemia 285 10 (3.5)
Osteoarthritis 182 4 (2.2)
Hepatitis B 176 1 (0.6)
Juvenile idiopathic arthritis 169 13 (7.7)
Polymyalgia rheumatica 146 0 (0)
Vasculitis/Wegener’s granulomatosis 107 5 (4.7)
Tuberculosis 96 33 (34.3)
Polymyositis/dermatomyositis 75 0 (0)
Fibromyalgia 74 2 (2.7)
Gout and pseudogout 58 0 (0)
*ACPA = anti-citrullinated peptide antibody; CREST = calcinosis, Raynaud’s phenomenon, esophageal dysmotility,
sclerodactyly, telangiectasias syndrome.
Adapted from Aggarwal et al. [51].
Table 6.
Detection of ACPAs in diseases other than rheumatoid arthritis.
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rheumatologists use the term “early” for symptoms shorter than 3 months.
Currently, in general, early RA patients are preferentially regarded as those with
symptoms of less than 3 months duration [54].
Besides the notion of disease duration, clinical practice informs us that there are a
number of existing clinical factors which may also suggest early RA. These may
include persistent pain in multiple joints despite normal joint radiography without
fulfillment of RA classification criteria. Similarly, because clinicians may care for RA
patient longitudinally over time, they are more likely to appreciate early manifesta-
tions, even in hindsight, as exemplified by the following common clinical situations:
1.Patients in the early stage of RA may not manifest soft tissue swelling
(arthritis) of three or more joints as described in the 1987 classification criteria.
2.Patients in the early stage of RA may not necessarily present with
unequivocally symmetric swelling (arthritis).
3.Patients in the very early stage of RA may not demonstrate serological
abnormalities such as elevated acute-phase reactants during which time CRP
and ESR are often unremarkable.
4. Inclusion of the presence of autoantibodies as major criteria for diagnosis
may not be fair, considering that a significant proportion of patients are
seronegative. As evidence suggests that seronegative RA represents a disease
entity clinically and immunogenetically distinct from seropositive RA, it may
well be inappropriate to apply RF to a mixed population of seropositive and
seronegative patients [55].
5.Almost all RA patients have joint symptoms in the hands; even though the
knee, ankle, or foot joint symptoms may precede hand pain, most patients
have some joint pain of the hands at the time of presentation.
On the basis of these fundamental understandings, we aimed to develop
practically useful criteria for the early diagnosis of RA by integrating Gd contrast-
enhanced MRI findings with clinical manifestations of the disease.
4. Benefits of MRI in diagnosing RA
Radiographs are the current gold standard for evaluating joint damage in RA,
and it is likely that radiography will continue to be used in daily clinical practice for
monitoring arthritis disease progression. However, conventional radiography is not
sensitive enough for depicting bone damage in early disease and is also insufficient
for assessing synovial inflammation. These limitations have led to emerging interest
in the multiplanar imaging abilities of MRI in RA and to wider use of MRI for
assessing synovitis and bone damage [56].
4.1 Basic principles of MRI and RA pathology on MRI
The principles of MRI are briefly explained here. Upon being placed in external
magnetic fields, hydrogen protons in human tissue align. They acquire energy
(resonance) when excited by an external electro-magnetic pulse at a characteristic
resonance frequency, with a consequent decrease in longitudinal magnetization and
increase in transverse magnetization. When the pulse is turned off, protons return
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to their previous low-energy state. The net movement of hydrogen protons elicits an
electric current that is measured as the MR signal [57]. The presentation of particu-
lar tissues depends on their hydrogen proton content. In common MRI sequences, a
T1-weighted (T1W) image represents fat-containing tissues, for example, the high
signal of the bone marrow. By contrast, on T2W images, not only fat but fluid
demonstrates high signal. The available techniques of fat suppression eliminate high
signal from fat, consequently making fluid and inflammation better evident.
MRI can be used to assess inflammation (synovitis and bone edema) and damage
(bone erosion) in the joint. Synovitis is depicted as an area in the synovial com-
partment that shows enhancement (signal intensity increase) on T1-weighted
images after venous injection of gadolinium contrast. MRI bone erosion is visualized
as a sharply marginated bone lesion, with correct juxta-articular localization and
typical signal characteristics, i.e., loss of normal low-signal intensity of the cortical
bone and loss of normal high-signal intensity of the trabecular bone on T1-weighted
images. MRI bone edema is visualized as a lesion within the trabecular bone, with
ill-defined margins and signal characteristics consistent with increased water con-
tent, i.e., high-signal intensity on T2-weighted fat-saturated and STIR images and
low-signal intensity on T1-weighted images. Bone edema may occur alone or sur-
rounding an area of erosion or other bone abnormality. Outcome Measures in
Rheumatology (OMERACT), an independent initiative of international health pro-
fessionals serving for the validation of clinical and radiographic outcome measures,
has iteratively developed an RA-MRI scoring system (RAMRIS) framework for the
evaluation of inflammatory and destructive changes in RA hands (metacarpo-
phalangeal, MCP, joints) and wrists (carpal bones, distal radius, distal ulna,
metacarpal bases) [58].
4.2 MRI of synovitis
Since synovitis is the earliest abnormality to occur in RA, MR imaging of syno-
vitis is currently the best way to identify the earliest changes critical for early
diagnosis of RA. MRI signatures of synovitis include increased synovial volume,
increased water content, and contrast enhancement, i.e., increased signal intensity
after intravenous injection of contrast material.
Synovitis reveals intermediate-to-low-signal intensity on T1-weighted images,
whereas due to the increased water content of synovitis, various signal intensities
can be viewed on T2-weighted images including the high signal of hypervascular
synovium, as well as the low-signal characteristic of fibrosis.
The use of intravenous Gd-based contrast material plays an important role in
MRI identification of synovitis. A number of dynamic MRI studies have demon-
strated a good correlation between MRI synovium volume estimates and arthro-
scopic and histological inflammation scores [59]. The most used contrast material
for evaluating synovitis is the paramagnetic agent, gadolinium-diethylenetriamine
penta-acid (Gd-DTPA). This agent shortens the relaxation time of adjacent tissues,
thereby improving the contrast between tissues on imaging. Uptake of Gd-DTPA
depends upon vascularity and capillary permeability of tissues, making it particu-
larly useful in visualizing sites of inflammation.
Contrast-enhanced T1-weighted images are sensitive and specific in the assess-
ment of acute synovitis. After intravenous administration of Gd-DTPA, acute
synovitis enhances rapidly and intensely, unlike joint effusion, which does not
enhance in the early phase. Early-phase enhancement lasts for approximately 5 min
after contrast injection [60]. Since gadolinium may diffuse into the synovial joint
fluid, images acquired more than 10 min after injection may not accurately depict
the extent of synovitis. In contrast, joint fluid enhancement appears within minutes
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and reaches a plateau after 30 min. The use of fat suppression increases visual
contrast between the inflamed synovium and adjacent structures on contrast-
enhanced T1-weighted images [61]. OMERACT defines synovitis as an area in the
synovial compartment with increased contrast enhancement whose thickness
exceeds the width of normal synovium [58]. For the evaluation of synovitis in early
RA, we used coronal Gd-enhanced fat-suppressed T1-weighted MR images from
both hands. The hand was chosen for MRI assessment given that is the most
clinically affected area in RA. Figure 5 represents fat-suppressed contrast-enhanced
MRI from the volar aspect of the hand in a patient with early RA in our study, in
whom radiographic assessment was normal. Remarkable synovial enhancement at
the PIP, MCP, as well as wrist joints is noted.
5. Approach to the formulation of diagnostic criteria for early RA
5.1 Characteristics of contrast-enhanced MRI in active RA
First of all, we need to properly incorporate clinically significant MRI findings
into our diagnostic criteria for early RA. Therefore, at the outset, preliminary
studies of Gd-enhanced MRI were conducted to distinguish characteristics of syno-
vial MR images in active RA, using 20 patients with definitive clinical diagnoses of
RA (17 women, 3 men, ages 21–72 years, mean age 47.8 years), consisting of 17
active cases and 3 inactive cases in remission [40–43].
The MR imaging protocol we used is as follows: MR imaging of the hand was
performed with a 1.5-Tesla superconducting magnet (MRT 200 FX/II, Toshiba)
equipped with a circular surface coil 20 cm in diameter. Multiple coronal MR
images of the hand were obtained using a fat-suppressed T1-weighted spin-echo
sequence (repetition time msec/echo time msec = 380/20, 4 mm section thickness
with 1 mm intersection gap). Contrast-enhanced images were obtained after bolus
injection of 0.1 mmol/kg gadopentetate dimeglumine (Magnevist, Schering) into a
Figure 5.
MR imaging signs of synovitis in our study. Fat-suppressed contrast-enhanced T1-weighted coronal MR imaging
from the volar aspect of the hand in a patient with early RA, in whom radiographic assessment was normal.
There is marked synovial enhancement at the joints of PIP, MCP, as well as wrist joints.
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vein in the arm. MR images were acquired within 5 min after injection to avoid
diffusion of the contrast material into joints.
As a result, we found bilateral enhancement in the wrist joints (carpal bones,
distal radius, distal ulna, metacarpal bases) in 17 cases of active RA and the
metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joints in 14 cases.
By contrast, no enhancement was seen in any of the three inactive cases in remis-
sion. On the basis of these convincing results, we decided to focus on the bilateral
enhancement of the synovia in the PIP, MCP, or wrist joints, which may best
characterize the MRI findings of synovitis associated with active RA.
Thus, we established our preliminary criteria for the diagnosis of early RA using
MR imaging. These preliminary criteria were comprised of two steps with the first
requiring clinical findings suggestive of RA, including polyarthralgia of hands in
three joints or more (“entry criteria”). The second step involved MRI findings
indicating bilateral synovial enhancement seen in any PIP, MCP, or wrist joints on
Gd-enhanced MRI (“MRI criteria”). Bilateral involvement of PIP, MCP, or wrist
joints is acceptable though absolute symmetry is not required. RA was defined by
fulfilling the both entry criteria and MRI criteria.
To evaluate the performance of these preliminary criteria, we conducted a
provisional study to investigate the difference between the early RA and the other
conditions than RA in Gd-MRI findings. We selected patients with early RA,
defined as those carrying a definitive clinical diagnosis of RA made by a board-
certified, trained rheumatologist, but without having radiographic changes. Sixteen
patients (15 women, 1 man, aged 19–76 years, mean age 49.9 years) with early RA
and 11 non-RA controls (9 women, 2 men, 19–52 years, mean age 41.7 years), who
fulfilled the entry criteria, were enrolled. Non-RA controls consisted of patients
with systemic lupus erythematosus (2 cases), Sjögren’s syndrome (one case),
Behçet’s disease (one case), palindromic rheumatoid arthritis (one case), reactive
arthritis (two cases), viral arthritis (one case), and nonspecific transient self-
limiting arthritis (three cases). We evaluated the performance of the preliminary
criteria among cases that fulfilled entry criteria, including sensitivity and specificity
analyses. Our preliminary MRI criteria showed 100% sensitivity, 73% specificity,
and 89% accuracy in differentiating RA from other conditions.
Since that study, from daily experience using contrast-enhanced MRI in a
large number of clinical cases, we have found that enhancement in the synovium
may also be observed occasionally in patients with systemic lupus erythematosus,
dermatomyositis, polymyositis, mixed connective tissue disease, and Behçet’s
disease.
5.2 Proposed “diagnostic criteria for early RA with MRI findings”
On the basis of our preliminary studies, we created provisional criteria under the
title “diagnostic criteria for early RA with MRI findings” (Table 7).
These provisional diagnostic criteria comprise two domains. The first domain
consists of clinical findings suggestive of RA and includes entry criteria requiring
polyarthralgia of hands (joint pain of three or more joint areas confirmed by a
physician) and exclusion criteria that exclude other rheumatic conditions, i.e.,
systemic lupus erythematosus (SLE), dermatomyositis and polymyositis (PM/DM),
mixed connective tissue disease (MCTD), primary Sjögren’s syndrome (SS), and
Behçet’s disease (BD). The second domain constitutes the MRI criteria, requiring
Gd-enhanced MRI findings indicating bilateral synovial enhancement seen in any
PIP, MCP, or wrist joints. Bilateral involvement of PIP, MCP, or carpal joints of
wrists is acceptable, and absolute symmetry is not required to meet the domain
criteria. Early RA is defined by fulfilling all conditions of both domains.
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5.3 Validation of “diagnostic criteria for early RA with MRI findings” in
prospective study
We evaluated our provisional diagnostic criteria for early rheumatoid arthritis
with MRI findings in a prospective study, approved by our institutional review
board. The validity of the diagnostic criteria was assessed by acquisition of final
diagnoses at the end of the clinical follow-up of a certain duration. Final diagnoses
were made comprehensively. Subjects included patients presenting with
polyarthralgia who visited rheumatology clinic at our institution. At the end of
recruitment, we enrolled 50 consecutive patients including 9 men and 41 women
(mean age, 44 years; range, 19–74 years old). All enrollees met entry criteria
defined as the presence of polyarthralgia in hands in three or more joint areas. The
diagnosis of RA or non-RA was made after careful clinical follow-up by trained
rheumatologists. The final diagnosis of RA was established according to physical
Diagnosis of RA is defined by fulfilling all conditions of following both domains
Clinical domain—clinical findings suggestive of RA:
1. Entry criteria: presence of polyarthralgia in hands (three or more joint areas)
2. Exclusion criteria: exclusion of other rheumatic conditions, i.e.,
systemic lupus erythematosus (SLE),
dermatomyositis and polymyositis (PM/DM),
mixed connective tissue disease (MCTD),
primary Sjögren’s syndrome (SS), and
Behçet’s disease (BD)
• If case meets entry criteria and does not meet any exclusion criteria, proceed to MRI criteria
MRI domain—MRI findings suggestive of RA:
3. MRI criteria: bilateral synovial enhancement on Gd-enhanced MRI*
in the proximal interphalangeal (PIP), or
metacarpophalangeal (MCP), or
wrist joints
*Symmetrical involvement in bilateral joints not required.
Table 7.
The diagnostic criteria for early RA with MRI findings (proposal).
Subjects: 50 cases (41 women and 9 men, average age = 44 years old)
Observation period: mean duration = 776 days
Drop out: two cases
Final diagnoses:
Disease category n
RA 26
Non-RA 22
Arthritis related to viral infection
Sjögren’s syndrome
Osteoarthritis
Reactive arthritis
Cryoglobulinemia
Palindromic rheumatism
Unclassified self-limited arthritis
3
2*
4
1
1
1
10
*Primary Sjögren’s syndrome diagnosed during the study period.
Table 8.
Demographic profiles of patients with RA and non-RA diseases.
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findings compatible with RA or radiographic changes specific for RA and after
ruling out other disease conditions. The average duration of follow-up from first
visit was 776 days (range, 117–2161 days). Two of the 50 enrolled patients were lost
to follow-up prior to diagnosis, and subsequent medical information was not avail-
able; they were excluded from the analysis.
After a thorough follow-up period of careful clinical observation, a final pool of
48 patients had confirmed diagnoses: 26 patients had RA, and 22 had non-RA
conditions. Patient disease profiles are shown in Table 8. Statistics of diagnostic
performance is presented in Table 9. The proposed diagnostic criteria for early RA
with MRI findings was able to diagnose 25 of 26 patients with RA with high accu-
racy. False positives occurred in three patients, yielding a sensitivity of 96%, spec-
ificity of 86%, and accuracy of 92%, indicating high diagnostic performance. In
particular, it should be noted that the criteria effectively ruled out RA with a high
negative predictive value of 95%.
Thus, our study objectively demonstrated that the “diagnostic criteria of early
rheumatoid arthritis with MRI findings” was clinically quite effective in making
early diagnoses of RA, though there is a need to validate the criteria with a larger
sample of patients.
6. Conclusions
The combined use of MRI measures and clinical findings for the diagnosis of
early RA holds considerable promise for improving the accuracy of early diagnosis
of RA and may be effective in facilitating earlier use of interventions for this
progressive disease.
The increasing use of MRI for the diagnosis of RA may come at cost, and
therefore inappropriate use and overuse should be avoided. Nonetheless, MRI
provides a great advantage over conventional radiography in terms of quantita-
tively identifying inflamed synovium tissues with a high degree of sensitivity. The
incorporation of MRI findings together with clinical findings into the criteria for the
diagnosis of early RA demonstrates excellent diagnostic performance.
Early and accurate diagnosis, which can be achieved through the introduction of
our proposed criteria, can prevent prolonged anxiety and suffering in RA patients
who live with persistent joint pain and disability. Furthermore, early diagnosis may
lead to a number of social benefits including enabling patients an earlier return to
work and to active lives through early treatment.
We believe our novel diagnostic criteria for early RA integrated with MRI
findings will contribute substantially to daily clinical practice as well as to the
epidemiology and basic science of RA.
No. of
patients
True
positive
True
negative
False
positive
False
negative
Sensitivity
(%)
Specificity
(%)
Accuracy
Final Dx RA Non-RA
26 22
Proposed
criteria
28 20 25 19* 3** 1 96% 86% 92%
ACR 1987
criteria
19 29 18 21 1 8 69% 95% 81%
*Predictive value of negative results: 95%.
**False positive: cryoglobulinemia = 1; arthritis related to viral infection = 1, osteoarthritis = 1.
Table 9.
Sensitivity, specificity, and accuracy of proposed criteria for rheumatoid arthritis.
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